Akero Therapeutics Inc (AKRO)
19.94
-0.80
(-3.84%)
USD |
NASDAQ |
May 17, 16:00
19.94
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics Cash from Financing (Quarterly): 366.94M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 366.94M |
December 31, 2023 | 0.502M |
September 30, 2023 | 0.806M |
June 30, 2023 | 336.86M |
March 31, 2023 | 15.15M |
December 31, 2022 | 2.723M |
September 30, 2022 | 217.90M |
June 30, 2022 | 34.88M |
March 31, 2022 | 0.132M |
December 31, 2021 | 0.243M |
September 30, 2021 | 0.069M |
June 30, 2021 | 0.266M |
March 31, 2021 | 0.024M |
Date | Value |
---|---|
December 31, 2020 | 0.059M |
September 30, 2020 | 202.78M |
June 30, 2020 | 0.10M |
March 31, 2020 | 0.164M |
December 31, 2019 | 0.115M |
September 30, 2019 | -1.607M |
June 30, 2019 | 98.20M |
March 31, 2019 | -0.72M |
December 31, 2018 | 70.22M |
September 30, 2018 | 0.00 |
June 30, 2018 | 14.78M |
March 31, 2018 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.607M
Minimum
Sep 2019
366.94M
Maximum
Mar 2024
63.82M
Average
0.384M
Median
Cash from Financing (Quarterly) Benchmarks
89bio Inc | 21.03M |
Madrigal Pharmaceuticals Inc | 573.71M |
Viking Therapeutics Inc | 606.04M |
Ionis Pharmaceuticals Inc | 23.57M |
Galectin Therapeutics Inc | 10.00M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -35.14M |
Cash from Investing (Quarterly) | 57.85M |
Free Cash Flow | -155.88M |
Free Cash Flow Per Share (Quarterly) | -0.5925 |
Free Cash Flow Yield | -14.05% |